Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
370 Leser
Artikel bewerten:
(1)

PRA Health Sciences, Inc.: PRA Health Sciences, Symphony Health Launch Metys National Market Measurement Tool

The first of its kind, Metys delivers accurate, reliable data quickly through a single access point

RALEIGH, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health's new national market measurement tool - Metys (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).

The first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive. Now life sciences and other industries are better equipped to manage diverse portfolios with accuracy, reliability and agility.

Powered by IDV, the company's Integrated Dataverse, Metys intelligently integrates prescriber, payer, and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. Speed, ease of access, and insights are all hallmarks of Metys' customizable dashboards and reporting. Metys is also the only national market measurement solution in the industry that includes linked diagnosis subgroups to projected prescriptions and writers.

"Because understanding, measuring and influencing treatment decisions is increasingly complex, PRA and Symphony Health have developed a solution that quickly and efficiently brings all of the data to clients' fingertips within the Metys platform," said Doug Fulling, President of Symphony Health. "This offering affirms our commitment to serving our clients at the highest level with tools that will move their business forward, while also reinforcing our culture of innovation and excellence."

For more information about Metys visit www.symphonyhealth.com.

ABOUT PRA HEALTH SCIENCES

PRA.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES:
Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435

ABOUT SYMPHONY HEALTH

A wholly-owned subsidiary of PRA Health Sciences, Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment, and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics, and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information about Symphony Health, please visit www.symphonyhealth.com.

A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d0f7fa-d592-4014-a193-04bd810547f9

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2019 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.